{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:37:59Z","timestamp":1768869479500,"version":"3.49.0"},"reference-count":20,"publisher":"FapUNIFESP (SciELO)","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Huainan Science and Technology Bureau","award":["2018B54"],"award-info":[{"award-number":["2018B54"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Assoc. Med. Bras."],"abstract":"<jats:p>SUMMARY  OBJECTIVE: The aim of this study was to investigate the association between lipoprotein(a) and coronary heart disease risk in type 2 diabetes mellitus patients and evaluate the effectiveness of statin therapy.  METHODS: This retrospective analysis included 120 patients diagnosed with type 2 diabetes mellitus. Of these, 90 patients diagnosed with coronary heart disease via coronary angiography received rosuvastatin treatment for over 6 months. The remaining 30 patients exhibited no coronary heart disease or other diabetic macrovascular complications and had not received any lipid-lowering treatment. Patients with type 2 diabetes mellitus and coronary heart disease were categorized into two groups based on the severity of coronary lesions. Baseline characteristics and blood lipid data were compared among groups. Logistic regression analysis was employed to investigate the association between lipoprotein(a) and coronary heart disease risk in type 2 diabetes mellitus patients. Receiver operating characteristic curves were utilized to evaluate the diagnostic value of lipoprotein(a) for coronary heart disease.  RESULTS: Compared with the control group, lipoprotein(a) levers were higher in both the mild and severe groups. Logistic regression analysis demonstrated that lipoprotein(a) is independently associated with the risk of coronary heart disease in type 2 diabetes mellitus patients. The area under the receiver operating characteristic curve for lipoprotein(a) was 0.729. When lipoprotein(a) was 97.5 mg\/L, the diagnosis of coronary heart disease had high sensitivity and specificity. After statin therapy, high-density lipoprotein cholesterol and apolipoprotein A levels increased, while other lipid parameters decreased. However, the lipoprotein(a) level decrease was not statistically significant.  CONCLUSION: Lipoprotein(a) is an independent risk factor for coronary heart disease in type 2 diabetes mellitus patients. Lipid-lowering therapy with statins alone cannot reduce lipoprotein(a) levels.<\/jats:p>","DOI":"10.1590\/1806-9282.20240870","type":"journal-article","created":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T07:19:22Z","timestamp":1742627962000},"source":"Crossref","is-referenced-by-count":1,"title":["Association between lipoprotein(a) and coronary heart disease risk in type 2 diabetes mellitus and evaluation of statin treatment effects"],"prefix":"10.1590","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-4407-5315","authenticated-orcid":false,"given":"Li","family":"Li","sequence":"first","affiliation":[{"name":"Bengbu Medical University,  People's Republic of China; Anhui University of Science and Technology,  People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3489-4169","authenticated-orcid":false,"given":"Liwu","family":"Xu","sequence":"additional","affiliation":[{"name":"Bengbu Medical University,  People's Republic of China; Anhui University of Science and Technology,  People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"11795514231220780","DOI":"10.1177\/11795514231220780","article-title":"Cardiometabolic risk factors associated with type 2 diabetes mellitus: a mechanistic insight","volume":"16","author":"Chakraborty S","year":"2023","journal-title":"Clin Med Insights Endocrinol Diabetes"},{"issue":"4","key":"ref2","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.010932","article-title":"Relationship between low-density lipoprotein cholesterol and lipoprotein(a) lowering in response to PCSK9 inhibition with evolocumab","volume":"8","author":"Shapiro MD","year":"2019","journal-title":"J Am Heart Assoc"},{"issue":"8","key":"ref3","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jacc.2021.11.058","article-title":"Independent association of lipoprotein(a) and coronary artery calcification with atherosclerotic cardiovascular risk","volume":"79","author":"Mehta A","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"ref4","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12967-023-04836-7","article-title":"Risk factors for carotid plaque formation in type 2 diabetes mellitus","volume":"22","author":"Chen J","year":"2024","journal-title":"J Transl Med"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ejim.2023.10.013","article-title":"Residual cardiovascular risk: when should we treat it?","volume":"120","author":"Gomez-Delgado F","year":"2024","journal-title":"Eur J Intern Med"},{"issue":"1","key":"ref6","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.pcd.2023.11.010","article-title":"Associations between physical activity and all-cause and cardiovascular mortality in adults with type 2 diabetes mellitus: a prospective cohort study from NHANES 2007-2018","volume":"18","author":"Lu J","year":"2024","journal-title":"Prim Care Diabetes"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"10742484231189597","DOI":"10.1177\/10742484231189597","article-title":"Residual atherosclerotic cardiovascular disease risk: focus on non-high-density lipoprotein cholesterol","volume":"28","author":"Luo Y","year":"2023","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2020.03.003","article-title":"The dedicated \"Lp(a) clinic\": a concept whose time has arrived?","volume":"300","author":"Tsimikas S","year":"2020","journal-title":"Atherosclerosis"},{"issue":"1","key":"ref9","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12933-020-01083-8","article-title":"Lipoprotein (a) predicts recurrent worse outcomes in type 2 diabetes mellitus patients with prior cardiovascular events: a prospective, observational cohort study","volume":"19","author":"Zhang Y","year":"2020","journal-title":"Cardiovasc Diabetol"},{"issue":"5","key":"ref10","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1080\/07853890.2020.1775287","article-title":"Lipoprotein(a) in atherosclerosis: from pathophysiology to clinical relevance and treatment options","volume":"52","author":"Rehberger Likozar A","year":"2020","journal-title":"Ann Med"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.coph.2021.08.013","article-title":"Dyslipidemia and diabetes mellitus: role of lipoprotein species and interrelated pathways of lipid metabolism in diabetes mellitus","volume":"61","author":"Kane JP","year":"2021","journal-title":"Curr Opin Pharmacol"},{"issue":"39","key":"ref12","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement","volume":"43","author":"Kronenberg F","year":"2022","journal-title":"Eur Heart J"},{"issue":"9","key":"ref13","doi-asserted-by":"crossref","first-page":"621","DOI":"10.26599\/1671-5411.2023.09.008","article-title":"2023 China guidelines for lipid management","volume":"20","author":"Li JJ","year":"2023","journal-title":"J Geriatr Cardiol"},{"issue":"1","key":"ref14","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach F","year":"2020","journal-title":"Eur Heart J"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"123586","DOI":"10.1016\/j.ijbiomac.2023.123586","article-title":"Exploring the role of lipoprotein(a) in cardiovascular diseases and diabetes in Chinese population","volume":"233","author":"Hussain Z","year":"2023","journal-title":"Int J Biol Macromol"},{"issue":"1","key":"ref16","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1161\/ATV.0000000000000147","article-title":"Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American Heart Association","volume":"42","author":"Reyes-Soffer G","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"8S","key":"ref17","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/j.cjca.2024.05.004","article-title":"Medications for lipid control: statins vs newer drugs","volume":"40","author":"McPherson R","year":"2024","journal-title":"Can J Cardiol"},{"issue":"24","key":"ref18","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1093\/eurheartj\/ehz310","article-title":"Statin therapy increases lipoprotein(a) levels","volume":"41","author":"Tsimikas S","year":"2020","journal-title":"Eur Heart J"},{"issue":"11","key":"ref19","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/j.metabol.2016.08.007","article-title":"Effect of extended-release niacin on plasma lipoprotein(a) levels: a systematic review and meta-analysis of randomized placebo-controlled trials","volume":"65","author":"Sahebkar A","year":"2016","journal-title":"Metabolism"},{"issue":"48","key":"ref20","doi-asserted-by":"crossref","first-page":"5018","DOI":"10.1093\/eurheartj\/ehad682","article-title":"Oral strategies to target proprotein convertase subtilisin\/kexin type 9 and lipoprotein(a): the new frontier of lipid lowering","volume":"44","author":"Norata GD","year":"2023","journal-title":"Eur Heart J"}],"container-title":["Revista da Associa\u00e7\u00e3o M\u00e9dica Brasileira"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_pdf&pid=S0104-42302025000100610&tlng=en","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T07:19:54Z","timestamp":1742627994000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0104-42302025000100610&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025]]}},"alternative-id":["S0104-42302025000100610"],"URL":"https:\/\/doi.org\/10.1590\/1806-9282.20240870","relation":{},"ISSN":["1806-9282","0104-4230"],"issn-type":[{"value":"1806-9282","type":"electronic"},{"value":"0104-4230","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"e20240870"}}